Terms: = Bone cancer AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Staging
16 results:
1. Head-to-Head Comparison of [
Ballal S; Yadav MP; Roesch F; Raju S; Satapathy S; Sheokand P; Moon ES; Martin M; Awarwal S; Tripathi M; Bal C
Thyroid; 2023 Aug; 33(8):974-982. PubMed ID: 37171126
[No Abstract] [Full Text] [Related]
2. The predictive value of sentinel node biopsy in early breast cancer after neo-adjuvant chemotherapy: A prospective study.
Najim O; Dockx Y; Huyghe I; van den Wyngaert T; Papadimitriou K; Tjalma WAA; Huizing MT
Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():108-111. PubMed ID: 30145524
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid cancer: Superiority in Detecting bone Metastases.
Castroneves LA; Coura Filho G; de Freitas RMC; Salles R; Moyses RA; Lopez RVM; Pereira MAA; Tavares MR; Jorge AAL; Buchpiguel CA; Hoff AO
J Clin Endocrinol Metab; 2018 Sep; 103(9):3250-3259. PubMed ID: 29846642
[TBL] [Abstract] [Full Text] [Related]
4. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system.
Machens A; Dralle H
Ann Surg; 2013 Feb; 257(2):323-9. PubMed ID: 22968075
[TBL] [Abstract] [Full Text] [Related]
6. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer.
Soussan M; Nataf V; Kerrou K; Grahek D; Pascal O; Talbot JN; Montravers F
Nucl Med Commun; 2012 Jul; 33(7):775-9. PubMed ID: 22546877
[TBL] [Abstract] [Full Text] [Related]
7. Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer.
Kraeber-Bodéré F; Salaun PY; Oudoux A; Goldenberg DM; Chatal JF; Barbet J
Cancer; 2010 Feb; 116(4 Suppl):1118-25. PubMed ID: 20127952
[TBL] [Abstract] [Full Text] [Related]
8. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
[TBL] [Abstract] [Full Text] [Related]
9. staging performance of carbon-11 choline positron emission tomography/computed tomography in patients with bone and soft tissue sarcoma: comparison with conventional imaging.
Tateishi U; Yamaguchi U; Maeda T; Seki K; Terauchi T; Kawai A; Arai Y; Moriyama N; Kakizoe T
Cancer Sci; 2006 Oct; 97(10):1125-8. PubMed ID: 16925579
[TBL] [Abstract] [Full Text] [Related]
10. Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients.
Szavcsur P; Godény M; Bajzik G; Lengyel E; Repa I; Trón L; Boér A; Vincze B; Póti Z; Szabolcs I; Esik O
Eur J Surg Oncol; 2005 Mar; 31(2):183-90. PubMed ID: 15698736
[TBL] [Abstract] [Full Text] [Related]
11. A rare case of bilateral stage IV adrenal neuroblastoma with multiple skin metastases in a neonate: diagnosis, management, and outcome.
Yanai T; Okazaki T; Yamataka A; Fujita H; Saito M; Lane G; Yamashiro Y; Miyano T
J Pediatr Surg; 2004 Dec; 39(12):1782-3. PubMed ID: 15616928
[TBL] [Abstract] [Full Text] [Related]
12. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract] [Full Text] [Related]
13. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract] [Full Text] [Related]
14. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
[TBL] [Abstract] [Full Text] [Related]
15. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers.
Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Ambros P; Ambros I; Ladanyi M; Eddy J; Bonilla MA; Gerald W
Eur J Cancer; 1997 Oct; 33(12):2117-20. PubMed ID: 9516865
[TBL] [Abstract] [Full Text] [Related]
16. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.
Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Herskovic T; Hanley D; Markowitz A; Dunn R; Siegel J; Kamal T; Goldenberg DM
J Clin Oncol; 1996 Apr; 14(4):1209-17. PubMed ID: 8648376
[TBL] [Abstract] [Full Text] [Related]
